Clinical Study on Exploring High Risk Factors Inducing the Progress of Diabetes

Exclusion Criteria

• •In the past month and currently taking glucocorticoids, steroids, thiazide diuretics, or atypical antipsychotic drugs
• •Some diseases that affect glucose tolerance: type 1 diabetes (T1DM), pancreatic exocrine disease, polycystic ovary syndrome and other endocrine diseases, autoimmune diseases, infection and trauma and other irritability factors
• •Diseases that may affect eating: mental illness, post gastrectomy, inflammatory bowel disease, uncontrolled thyroid disease.
• •Healthy subjects with a history of gestational diabetes or subjects with direct family members with a family history of diabetes
• •Pregnant or lactating women
• •Participate in any other clinical trials within 3 months prior to the trial
• •Blood donation or loss of ≥ 400mL within 8 weeks before the first cycle of the experiment
• •Clinically significant history of ECG abnormalities or family history of long QT syndrome (grandparents, parents, siblings) Suffering from any condition that significantly affects glucose absorption, distribution, metabolism, and excretion within 2 weeks prior to the experiment, or any condition that may pose a hazard to the subject, the detailed conditions are as follows:
• •1. History of inflammatory bowel disease, gastritis, ulcers, gastrointestinal or rectal bleeding
• •2. A significant history of gastrointestinal surgery (such as gastrectomy, gastroenterostomy, or intestinal resection),
• •3. history of pancreatic injury or pancreatitis or clinical evidence, or researchers' judgment of abnormal lipase and amylase,
• •4. abnormal liver function tests (such as ALT, AST, serum bilirubin), which are clinically significant, indicate liver disease, cirrhosis, or liver injury. (alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], alkaline phosphatase \[ALP\], glutamine transpeptidase \[GGT\], total bilirubin) greater than three times their respective upper limit of normal (ULN).
• •5. There is a history or evidence of renal dysfunction, manifested as clinically significant creatinine or urinary composition abnormalities (such as tubular type), or eGFR\<60 ml/min/1.73m2
• •6. Urinary tract obstruction or difficulty in emptying urine during screening period
• •Individuals with any form of medical/implant intolerance, including pacemakers, metal plates, or magnetic resonance imaging (MRI)
• •Individuals who have tested positive for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies, or syphilis (results within six months are exempt from testing)
• •Smokers who smoke more than 10 cigarettes or an equivalent amount of tobacco per day cannot stop smoking during the trial period
• •There is a history of drug or alcohol abuse within the 12 months prior to the trial, or evidence of abuse is found during laboratory testing during screening evaluation
• •During screening, lying blood pressure (after resting for 5 minutes) exceeds the range of 90-140mm Hg (including 90140) in systolic blood pressure, 50-90 mmHg (including 50, 90) in diastolic blood pressure, or heart rate (HR) exceeds the range of 50 bpm to 100 bpm (including 50100) in heart rate (HR)
• •Tumor patients
• •Participants are not suitable for the experiment